CONMED Corporation
CNMD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -0.29 | 0.15 | 0.12 |
| FCF Yield | 7.29% | 3.17% | 0.43% | 2.34% |
| EV / EBITDA | 12.06 | 22.47 | 473.02 | 30.29 |
| Quality | ||||
| ROIC | 7.99% | 5.22% | 3.85% | 2.05% |
| Gross Margin | 56.08% | 54.33% | 54.64% | 56.21% |
| Cash Conversion Ratio | 1.26 | 1.94 | -0.41 | 1.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.73% | 7.19% | 6.62% | 1.90% |
| Free Cash Flow Growth | 44.74% | 818.10% | -88.05% | 88.10% |
| Safety | ||||
| Net Debt / EBITDA | 3.67 | 5.02 | 131.56 | 4.19 |
| Interest Coverage | 5.37 | 3.29 | 2.42 | 1.07 |
| Efficiency | ||||
| Inventory Turnover | 1.66 | 1.79 | 1.43 | 1.91 |
| Cash Conversion Cycle | 221.85 | 218.78 | 266.09 | 209.45 |